Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09KAK
|
||||
| Former ID |
DPR000080
|
||||
| Drug Name |
NOX-F37
|
||||
| Indication | Acute and chronic heart failure [ICD9: 428; ICD10:I50] | Preclinical | [1] | ||
| Target and Pathway | |||||
| Target(s) | Vasopressin V1a receptor | Target Info | Antagonist | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Reactome | Vasopressin-like receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.